ArticleFrontiers in neurology
The effect of hyperbaric oxygen therapy on sleep quality across diverse patient populations.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sleep disturbances are common in aging, post-traumatic stress disorder (PTSD), and long COVID, often linked to neuroinflammation, autonomic dysregulation, and neurodegeneration. Hyperbaric oxygen therapy (HBOT) promotes neuroplasticity through the hyperoxic-hypoxic paradox, improving cerebral perfusion, mitochondrial function, and reducing inflammation. While HBOT benefits sleep in certain conditions, its general effects across clinical populations remain unclear. Methods: This retrospective longitudinal study evaluated Pittsburgh Sleep Quality Index (PSQI) changes in patients undergoing 60 HBOT sessions (2.0 ATA, 100% oxygen, 90 min, 5 days/week) at the Sagol Center. Participants included individuals treated for healthy aging ( Results: Among 395 patients (mean age at baseline 57.9 ± 14.6 years, 31% female), baseline PSQI scores were highest in PTSD. Post-HBOT, total PSQI scores improved significantly in all groups ( Conclusion: HBOT was associated with improvement in sleep quality across diverse conditions, with greatest benefit in patients with poorer baseline sleep. Findings support HBOT's potential as a sleep-modulating therapy, warranting controlled trials to characterize the patients that can benefit the most and elucidate mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.